Stryker Stock-Based Compensation Growth & History (SYK)
Stryker's stock-based compensation was $243.0M for fiscal 2025.
View full Stryker company overviewStryker annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $243.0M | $14.0M | +6.11% |
| 2024 | 2024-12-31 | $229.0M | $24.0M | +11.71% |
| 2023 | 2023-12-31 | $205.0M | $37.0M | +22.02% |
| 2022 | 2022-12-31 | $168.0M | −$3.0M | −1.75% |
| 2021 | 2021-12-31 | $171.0M | $29.0M | +20.42% |
| 2020 | 2020-12-31 | $142.0M | $15.0M | +11.81% |
| 2019 | 2019-12-31 | $127.0M | $8.0M | +6.72% |
| 2018 | 2018-12-31 | $119.0M | $6.0M | +5.31% |
| 2017 | 2017-12-31 | $113.0M | $16.0M | +16.49% |
| 2016 | 2016-12-31 | $97.0M | $11.0M | +12.79% |
| 2015 | 2015-12-31 | $86.0M | $9.0M | +11.69% |
| 2014 | 2014-12-31 | $77.0M | $1.0M | +1.32% |
| 2013 | 2013-12-31 | $76.0M | $1.0M | +1.33% |
| 2012 | 2012-12-31 | $75.0M | $0 | 0.00% |
| 2011 | 2011-12-31 | $75.0M | $6.0M | +8.70% |
| 2010 | 2010-12-31 | $69.0M | $7.0M | +11.29% |
| 2009 | 2009-12-31 | $62.0M | −$3.5M | −5.34% |
| 2008 | 2008-12-31 | $65.5M | $4.2M | +6.85% |
| 2007 | 2007-12-31 | $61.3M | — | — |
Stryker quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $54.0M | $5.0M | +10.20% |
| Q1 2026 | 2026-03-31 | $87.0M | $3.0M | +3.57% |
| Q4 2025 | 2025-12-31 | $48.0M | $3.0M | +6.67% |
| Q3 2025 | 2025-09-30 | $62.0M | $11.0M | +21.57% |
| Q2 2025 | 2025-06-30 | $49.0M | $3.0M | +6.52% |
| Q1 2025 | 2025-03-31 | $84.0M | −$3.0M | −3.45% |
| Q4 2024 | 2024-12-31 | $45.0M | $5.0M | +12.50% |
| Q3 2024 | 2024-09-30 | $51.0M | −$1.0M | −1.92% |
| Q2 2024 | 2024-06-30 | $46.0M | $7.0M | +17.95% |
| Q1 2024 | 2024-03-31 | $87.0M | $13.0M | +17.57% |
| Q4 2023 | 2023-12-31 | $40.0M | $12.0M | +42.86% |
| Q3 2023 | 2023-09-30 | $52.0M | $19.0M | +57.58% |
| Q2 2023 | 2023-06-30 | $39.0M | $3.0M | +8.33% |
| Q1 2023 | 2023-03-31 | $74.0M | $3.0M | +4.23% |
| Q4 2022 | 2022-12-31 | $28.0M | −$2.0M | −6.67% |
| Q3 2022 | 2022-09-30 | $33.0M | −$1.0M | −2.94% |
| Q2 2022 | 2022-06-30 | $36.0M | −$3.0M | −7.69% |
| Q1 2022 | 2022-03-31 | $71.0M | $3.0M | +4.41% |
| Q4 2021 | 2021-12-31 | $30.0M | $3.0M | +11.11% |
| Q3 2021 | 2021-09-30 | $34.0M | $5.0M | +17.24% |
| Q2 2021 | 2021-06-30 | $39.0M | $9.0M | +30.00% |
| Q1 2021 | 2021-03-31 | $68.0M | $12.0M | +21.43% |
| Q4 2020 | 2020-12-31 | $27.0M | −$5.0M | −15.63% |
| Q3 2020 | 2020-09-30 | $29.0M | −$3.0M | −9.38% |
| Q2 2020 | 2020-06-30 | $30.0M | $2.0M | +7.14% |
| Q1 2020 | 2020-03-31 | $56.0M | $21.0M | +60.00% |
| Q4 2019 | 2019-12-31 | $32.0M | $0 | 0.00% |
| Q3 2019 | 2019-09-30 | $32.0M | $2.0M | +6.67% |
| Q2 2019 | 2019-06-30 | $28.0M | $0 | 0.00% |
| Q1 2019 | 2019-03-31 | $35.0M | $6.0M | +20.69% |
| Q4 2018 | 2018-12-31 | $32.0M | $4.0M | +14.29% |
| Q3 2018 | 2018-09-30 | $30.0M | $3.0M | +11.11% |
| Q2 2018 | 2018-06-30 | $28.0M | $2.0M | +7.69% |
| Q1 2018 | 2018-03-31 | $29.0M | −$3.0M | −9.38% |
| Q4 2017 | 2017-12-31 | $28.0M | $2.0M | +7.69% |
| Q3 2017 | 2017-09-30 | $27.0M | $5.0M | +22.73% |
| Q2 2017 | 2017-06-30 | $26.0M | $5.0M | +23.81% |
| Q1 2017 | 2017-03-31 | $32.0M | $4.0M | +14.29% |
| Q4 2016 | 2016-12-31 | $26.0M | $5.0M | +23.81% |
| Q3 2016 | 2016-09-30 | $22.0M | $1.0M | +4.76% |
| Q2 2016 | 2016-06-30 | $21.0M | $0 | 0.00% |
| Q1 2016 | 2016-03-31 | $28.0M | $5.0M | +21.74% |
| Q4 2015 | 2015-12-31 | $21.0M | $2.0M | +10.53% |
| Q3 2015 | 2015-09-30 | $21.0M | $4.0M | +23.53% |
| Q2 2015 | 2015-06-30 | $21.0M | $1.0M | +5.00% |
| Q1 2015 | 2015-03-31 | $23.0M | $2.0M | +9.52% |
| Q4 2014 | 2014-12-31 | $19.0M | $0 | 0.00% |
| Q3 2014 | 2014-09-30 | $17.0M | −$2.0M | −10.53% |
| Q2 2014 | 2014-06-30 | $20.0M | $2.0M | +11.11% |
| Q1 2014 | 2014-03-31 | $21.0M | $1.0M | +5.00% |
| Q4 2013 | 2013-12-31 | $19.0M | $1.0M | +5.56% |
| Q3 2013 | 2013-09-30 | $19.0M | $1.0M | +5.56% |
| Q2 2013 | 2013-06-30 | $18.0M | $0 | 0.00% |
| Q1 2013 | 2013-03-31 | $20.0M | −$1.0M | −4.76% |
| Q4 2012 | 2012-12-31 | $18.0M | $1.0M | +5.88% |
| Q3 2012 | 2012-09-30 | $18.0M | −$1.0M | −5.26% |
| Q2 2012 | 2012-06-30 | $18.0M | −$1.0M | −5.26% |
| Q1 2012 | 2012-03-31 | $21.0M | $1.0M | +5.00% |
| Q4 2011 | 2011-12-31 | $17.0M | $2.1M | +14.09% |
| Q3 2011 | 2011-09-30 | $19.0M | $1.0M | +5.56% |
| Q2 2011 | 2011-06-30 | $19.0M | $1.7M | +9.83% |
| Q1 2011 | 2011-03-31 | $20.0M | $1.2M | +6.38% |
| Q4 2010 | 2010-12-31 | $14.9M | −$100,000 | −0.67% |
| Q3 2010 | 2010-09-30 | $18.0M | $2.7M | +17.65% |
| Q2 2010 | 2010-06-30 | $17.3M | $2.3M | +15.33% |
| Q1 2010 | 2010-03-31 | $18.8M | $2.1M | +12.57% |
| Q4 2009 | 2009-12-31 | $15.0M | — | — |
| Q3 2009 | 2009-09-30 | $15.3M | −$1.4M | −8.38% |
| Q2 2009 | 2009-06-30 | $15.0M | −$2.0M | −11.76% |
| Q1 2009 | 2009-03-31 | $16.7M | — | — |
| Q3 2008 | 2008-09-30 | $16.7M | — | — |
| Q2 2008 | 2008-06-30 | $17.0M | — | — |
Stryker stock-based compensation trends
Over the last five fiscal years, Stryker's stock-based compensation increased from $142.0M to $243.0M, a change of $101.0M. The latest reported quarter, Q2 2026, shows $54.0M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Stryker source filings ↗Community posts
Stryker completes ZuriMED acquisition to broaden its shoulder-repair offering
Stryker ($SYK) completed its acquisition of privately held ZuriMED, adding FiberLocker technology to its sports medicine business. The commercialized product is used to augment rotator cuff repair and is designed to increase the mechanical ...